Researchers Identified New Target for Heart Scarring
A study revealed that blocking a specific signaling pathway can reduce cardiac fibrosis in human and animal models.
Updated on Sept. 28, 2026 in Heart Disease
Live Poll
Should medical research prioritize targeting shared signaling pathways to treat common heart diseases?
Researchers at the Stanford Cardiovascular Institute identified a shared signaling pathway that triggers cardiac fibrosis. The study found that blocking this pathway with the compound CGS15943 effectively reduced heart scarring in lab and animal tests.
Why it matters
Cardiac fibrosis, characterized by the production of scar-forming matrix, currently has no FDA-approved therapies. This discovery highlights a shared signaling route that could lead to new treatments for patients with heart failure.
The study involved screening 4,000 distinct compounds against human induced pluripotent stem cells. CGS15943 was identified as an effective blocker for three specific types of adenosine receptors that activate scar-promoting genes.
The players
Stanford Cardiovascular Institute
This is a multidisciplinary research center focused on advancing cardiovascular medicine through basic science and clinical innovation.
The details
By using biosensors to track signaling pathways, the team determined that three adenosine receptors converge on the G beta-gamma signaling unit. Blocking this unit prevents fibroblasts from producing the excess collagen that leads to heart scarring.
Timeline
September 2026: The study was published in the journal Science.
The Big Picture
This discovery marks a shift in heart disease research by identifying a common genetic signaling mechanism across multiple adenosine receptors. The findings provide a new theoretical framework for targeting scar-producing cells in the heart.
There is currently no FDA-approved medication to treat cardiac fibrosis, meaning this remains a laboratory-stage discovery. Patients should await future clinical trials before any changes to current heart failure management protocols are recommended.
The takeaway
While these findings demonstrate success in reducing scarring in preclinical models, further human safety studies are necessary. Future therapeutic developments aim to specifically inhibit the cells responsible for harmful collagen accumulation.
Further reading
Learn more about the latest research on Heart Disease to understand how scientists are addressing chronic conditions.
More information
Read the complete Science journal study on cardiac fibrosis to review the methodology and results.
Source note: This article includes information reported by Technology Networks.
Live Poll
Should medical research prioritize targeting shared signaling pathways to treat common heart diseases?
